68Ga-PSMA-11

Phase 2

00%

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

4mo

NVSPhase 2$274.7B

68Ga-PSMA-11 Phase 2 Results Expected

68Ga-PSMA-11• Metastatic Castration-Resistant Prostate Cancer (mCRPC)20

Jun 17Estimated

00%

Competitive Landscape

0 competitors in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Drug Information

Target Indication

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Clinical Trial

Last updated: 1/24/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

NVS

Novartis AG

Related Pipeline

Neovascular Age-related Macular Degeneration

Renal Interstitial Fibrosis

Pathological Myopia

Non-Small Cell Lung Cancer

Prostatic Neoplasms